---
title: "Damora Therapeutics grants inducement stock options for 453,500 shares at USD 26.01 each"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291455952.md"
description: "Damora Therapeutics granted inducement stock options for 453,500 shares to nine newly hired non-executive employees on July 1, 2026. The options have a 10-year term with an exercise price of USD 26.01 per share. Vesting occurs at 25% after one year, followed by monthly vesting over the subsequent 36 months."
datetime: "2026-07-01T20:01:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291455952.md)
  - [en](https://longbridge.com/en/news/291455952.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291455952.md)
---

# Damora Therapeutics grants inducement stock options for 453,500 shares at USD 26.01 each

-   Damora Therapeutics granted inducement stock options to nine newly hired, non-executive employees on July 1, 2026. \* Awards cover 453,500 shares, 10-year term, exercise price USD 26.01 per share. \* Vesting set at 25% after one year, then monthly over the next 36 months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607011601PRIMZONEFULLFEED9755729) on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [DMRA.US](https://longbridge.com/en/quote/DMRA.US.md)

## Related News & Research

- [Damora Therapeutics posts corporate deck on mutCALR-targeted therapies for myeloproliferative neoplasms](https://longbridge.com/en/news/295448291.md)
- [Analyst Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target on Differentiated Clinical Strategy](https://longbridge.com/en/news/295521208.md)
- [Elkem terminates share option program, cancels 5,017,333 outstanding options](https://longbridge.com/en/news/295490899.md)
- [Arcutis Biotherapeutics grants 143,500 RSUs, 37,000 stock options to new hires under inducement plan](https://longbridge.com/en/news/295272046.md)
- [Faeth Therapeutics grants new-hire stock options for 11,000 shares at $25.5 each](https://longbridge.com/en/news/295272053.md)